The PETRUSHKA tool, developed by the University of Oxford, supports clinicians and patients to choose the antidepressant that is better tailored to each individual. It uses AI to combine clinical and demographic information with patient preferences, particularly around side effects, to support treatment personalization and shared decision-making in routine care.

The tool was tested in a large international randomized clinical trial across Brazil, Canada and the UK involving more than 500 adults with major depressive disorder (MDD) and launched in 2024.